

Recipharm invests in its US inhalation development service

Recipharm, the contract development and manufacturing organisation (CDMO), has invested USD 450,000 into its Research Triangle Park (RTP), North Carolina, US facility to install a SprayVIEW® system that will support inhalation and nasal product development.

The newly acquired system was installed alongside an environmental controlled aerosol collection chamber for inhalation testing and a metered dose inhaler (MDI) and dry powder inhaler (DPI) pilot process lab.

SprayVIEW® is a primary instrument for the characterisation of aerosols or sprays emitted from MDIs, soft mist inhalers and nasal sprays through the measurement of spray pattern and plume geometry. Both are important factors that affect spray performance and SprayVIEW® is an important tool that can visualise changes in other critical quality attributes (CQAs) of inhaled and nasal products.

Commenting on the investment, Lei Mao, Director Inhalation Science and Product Development at Recipharm said: "By employing the SprayVIEW® system and expanding our expertise in this technique, we are strengthening our capabilities in inhalation and nasal product development and manufacturing."

"Inhalation products are extremely complex to develop and manufacture and it is important to understand potential interactions between the formulation and the delivery device throughout the development stages. Acquiring a SprayVIEW® system has allowed our development team to successfully characterise a nasal spray product currently under development. In addition, our expertise in this technique adds new services for our innovator and generics customers who are coming to us for inhalation and nasal product development, as well as for standalone SprayVIEW® analysis."

These investments will enable Recipharm's development team to support customers in both innovative and generic inhalation and nasal product development and provide validation and transfer support when launching new inhalable drug products.

Recipharm recently launched Recipharm Inhalation Solutions™ which offers pharmaceutical companies a seamless outsourcing service from early stage development through to commercial manufacturing for inhalation products. Recipharm's inhalation development services include registration stability support, product characterisation, and in-vitro bioequivalence studies along with method development, validation and transfer support. This is complemented by commercial manufacturing capabilities providing an end-to-end solution.

For more information, visit <https://www.recipharm.com/solutions/recipharm-inhalation-solutions>



Contact information

Ann Flodin, Vice President & General Manager, ann.flodin@recipharm.com, +1 919 321 4021

For media enquiries, please contact Kate Hindhaugh at ramarketing: kate@ramarketingpr.com, + 44 (0)191 222 1242, ramarketingpr.com, Twitter: [@ramarketingpr](https://twitter.com/ramarketingpr), Facebook: [/ramarketingpr](https://facebook.com/ramarketingpr), LinkedIn: [/ramarketing](https://linkedin.com/company/ramarketingpr)

About Recipharm

Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 7,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm's turnover is approximately SEK 7.2 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.

For more information on Recipharm and our services, please visit www.recipharm.com